Download Files:
Domatinostat
$132 – $990
Products Details
Product Description
– Domatinostat (4SC-202 free base) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity against Lysine specific demethylase 1 (LSD1).
Web ID
– HY-16012A
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C23H21N5O3S
Citations
– J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2961-2966. |Am J Transl Res. 2020 Jun 15;12(6):2968-2983.
References
– [1]Pinkerneil M, et al. Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines. Target Oncol. 2016 Dec;11(6):783-798.|[2]Fu M, et al. 4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2016 Mar 4;471(2):267-73|[3]S.W.Henning, et al. Preclinical characterization of 4SC-202, a noval isotype specific HDAC inhibitor.|[4]Zhijun H, et al. Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells. Tumour Biol. 2016 Aug;37(8):10257-67.
CAS Number
– 910462-43-0
Molecular Weight
– 447.51
Compound Purity
– 99.43
SMILES
– O=C(NC1=CC=CC=C1N)/C=C/C2=CN(S(=O)(C3=CC=C(C4=CN(C)N=C4)C=C3)=O)C=C2
Clinical Information
– Phase 2
Research Area
– Cancer
Solubility
– DMSO : ≥ 58 mg/mL
Target
– Apoptosis;HDAC
Isoform
– HDAC1;HDAC10;HDAC11;HDAC2;HDAC3;HDAC5;HDAC9
Pathway
– Apoptosis;Cell Cycle/DNA Damage;Epigenetics
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
